nach oben

Erschienen in:

01.10.2014 | Original Paper

Apoptosis induction and anti-cancer activity of LeciPlex formulations

verfasst von: Vivek V. Dhawan, Ganesh V. Joshi, Ankitkumar S. Jain, Yuvraj P. Nikam, Rajiv P. Gude, Rita Mulherkar, Mangal S. Nagarsenker

Erschienen in: Cellular Oncology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cationic agents have been reported to possess anti-neoplastic properties against various cancer cell types. However, their complexes with lipids appear to interact differently with different cancer cells. The purpose of this study was to (i) design and generate novel cationic lecithin nanoparticles, (ii) assess and understand the mechanism underlying their putative cytotoxicity and (iii) test their effect on cell cycle progression in various cancer-derived cell lines. In addition, we aimed to evaluate the in vivo potential of these newly developed nanoparticles in oral anti-cancer delivery.

Methods

Cationic lecithin nanoparticles were generated using a single step nanoprecipitation method and they were characterized for particle size, zeta potential, stability and in vitro release. Their cytotoxic potential was assessed using a sulforhodamine B assay, and their effect on cell cycle progression was evaluated using flow cytometry. The nanoparticle systems were also tested in vivo for their anti-tumorigenic potential.

Results

In contrast to cationic agents alone, the newly developed nanoformulations showed a specific toxicity against cancer cells. The mechanism of toxic cell death included apoptosis, S and G2/M cell cycle phase arrest, depending on the type of cationic agent and the cancer-derived cell line used. Both blank and drug-loaded systems exhibited significant anti-cancer activity, suggesting a synergistic anti-tumorigenic effect of the drug and its delivery system.

Conclusions

Both in vitro and in vivo data indicate that cationic agents themselves exhibit broad anti-neoplastic activities. Complex formation of the cationic agents with phospholipids was found to provide specificity to the anti-cancer activity. These formulations thus possess potential for the design of effective anti-cancer delivery systems.

G. Fricker, T. Kromp, A. Wendel, A. Blume, J. Zirkel, H. Rebmann, C. Setzer, R.O. Quinkert, F. Martin, C. Müller-Goymann, Phospholipids and lipid-based formulations in oral drug delivery. Pharm. Res. 27, 1469–1486 (2010)PubMedCrossRef

I.F. Kretzer, D.A. Maria, R.C. Maranhão, Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion. Cell. Oncol. 35, 451–460 (2012)CrossRef

A.-L. Papa, A. Sidiqui, S.U.A. Balasubramanian, S. Sarangi, M. Luchette, S. Sengupta, R. Harfouche, PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic. Cell. Oncol. 36, 449–457 (2013)CrossRef

B.S. Anand, J.J. Romero BS, S.K. Sanduja, L.M. Lichtenberger, Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am. J. Gastroenterol 94, 1818–1822 (1999)PubMedCrossRef

X. Yan-yu, S. Yun-mei, C. Zhi-peng, P. Qi-neng, Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs. Int. J. of Pharm. 319, 162–168 (2006)CrossRef

Y.C. Kuoand, C.C. Wang, Cationic solid lipid nanoparticles with cholesterol-mediated surface layer for transporting saquinavir to the brain. Biotechnol. Prog. 30, 198–206 (2014)CrossRef

J.F. Fangueiro, T. Andreani, M.A. Egea, M.L. Garcia, S.B. Souto, A.M. Silva, E.B. Souto, Design of cationic lipid nanoparticles for ocular delivery: development, characterization and cytotoxicity. Int. J. Pharm. 461, 64–73 (2014)PubMedCrossRef

P. Khachane, A. Jain, V. Dhawan, G. Joshi, A. Date, R. Mulherker, and M. Nagarsenker. Cationic Nanoemulsions As Potential Carriers For Intracellular Delivery. Saudi Pharm. J. Accepted for Publication, (2014).

R. Cortesi, M. Campioni, L. Ravani, M. Drechsler, M. Pinotti, E. Esposito, Cationic lipid nanosystems as carriers for nucleic acids. New Biotechnol. 31, 44–54 (2014)CrossRef

10.

S. Doktorovova, R. Shegokar, E. Rakovsky, E. Gonzalez-Mira, C.M. Lopes, A.M. Silva, P. Martins-Lopes, R.H. Muller, E.B. Souto, Cationic solid lipid nanoparticles (cSLN): Structure, stability and DNA binding capacity correlation studies. Int. J. Pharm. 420, 341–349 (2011)PubMedCrossRef

11.

R.S. Dias, B. Lindman, M.G. Miguel, DNA interaction with catanionic vesicles. J. Phys. Chem. B. 106, 12600–12607 (2002)CrossRef

12.

M. Rosa, M. del Carmen Morán, M. da Graça Miguel, B. Lindman, The association of DNA and stable catanionic amino acid-based vesicles. Colloid. Surf. A: Physicochem. Eng. Asp. 301, 361–375 (2007)CrossRef

13.

P. Jokela, B. Joensson, A. Khan, Phase equilibria of catanionic surfactant-water systems. J. Phys. Chem. 91, 3291–3298 (1987)CrossRef

14.

A. Fischer, M. Hebrant, C. Tondre, Glucose encapsulation in catanionic vesicles and kinetic study of the entrapment/release processes in the sodium dodecyl benzene sulfonate/cetyltrimethylammonium tosylate/water system. J. Colloid Interface Sci. 248, 163–168 (2002)PubMedCrossRef

15.

T. Bramer, N. Dew, K. Edsman, Catanionic mixtures involving a drug: a rather general concept that can be utilized for prolonged drug release from gels. J. Pharm. Sci. 95, 769–780 (2006)PubMedCrossRef

16.

N. Dew, T. Bramer, K. Edsman, Catanionic aggregates formed from drugs and lauric or capric acids enable prolonged release from gels. J. Colloid Interface Sci. 323, 386–394 (2008)PubMedCrossRef

17.

A.A. Date, D. Srivastava, M.S. Nagarsenker, R. Mulherkar, L. Panicker, V. Aswal, P.A. Hassan, F. Steiniger, J. Thamm, A. Fahr, Lecithin-based novel cationic nanocarriers (LeciPlex) i: fabrication, characterization and evaluation. Nanomedicine. 6, 1309–1325 (2011)PubMedCrossRef

18.

E. Ito, K.W. Yip, D. Katz, S.B. Fonseca, D.W. Hedley, S. Chow, G.W. Xu, T.E. Wood, C. Bastianutto, A.D. Schimmer, Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer. Mol. Pharmacol. 76, 969–983 (2009)PubMedCrossRef

19.

S. Ramos, Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. The J. Nutr. Biochem. 18, 427–442 (2007)CrossRef

20.

S.-F. Chen, S. Nien, C.-H. Wu, C.-L. Liu, Y.-C. Chang, Y.-S. Lin, Reappraisal of the anticancer efficacy of quercetin in oral cancer cells. J. Chin. Med. 76, 146–152 (2013)

21.

F.H. Psahoulia, K.G. Drosopoulos, L. Doubravska, L. Andera, A. Pintzas, Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol. Cancer Ther. 6, 2591–2599 (2007)PubMedCrossRef

22.

C.-C. Chou, J.-S. Yang, H.-F. Lu, S.-W. Ip, C. Lo, C.-C. Wu, J.-P. Lin, N.-Y. Tang, J.-G. Chung, M.-J. Chou, Quercetin-mediated cell cycle arrest and apoptosis involving activation of a caspase cascade through the mitochondrial pathway in human breast cancer MCF-7 cells. Arch. of Pharm. Res. 33, 1181–1191 (2010)CrossRef

23.

C. Chen, J. Zhou, C. Ji, Quercetin: a potential drug to reverse multidrug resistance. Life Sci. 87, 333–338 (2010)PubMedCrossRef

24.

S.J. Oh, O. Kim, J.S. Lee, J. Kim, M.R. Kim, H.S. Choi, J.-H. Shim, K.W. Kang, Y.C. Kim, Inhibition of angiogenesis by quercetin in tamoxifen-resistant breast cancer cells. Food and Chem. Toxicol. 48, 3227–3234 (2010)CrossRef

25.

H. Li, X. Zhao, Y. Ma, G. Zhai, L. Li, H. Lou, Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J. Control. Release. 133, 238–244 (2009)PubMedCrossRef

26.

Z.-P. Yuan, L.-J. Chen, L.-Y. Fan, M.-H. Tang, G.-I. Yang, H.-S. Yang, X.-B. Du, G.-Q. Wang, W.-X. Yao, Q.-M. Zhao, Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin. Cancer Res 12, 3193–3199 (2006)PubMedCrossRef

27.

R. Mulherkar, A.P. Goud, A.S. Wagle, K. Naresh, M.B. Mahimkar, S.M. Thomas, S. Pradhan, M. Deo, Establishment of a human squamous cell carcinoma cell line of the upper aero-digestive tract. Cancer Lett. 118, 115–121 (1997)PubMedCrossRef

28.

A.A. Date, M.S. Nagarsenker, S. Patere, V. Dhawan, R. Gude, P. Hassan, V. Aswal, F. Steiniger, J. Thamm, A. Fahr, Lecithin-based novel cationic nanocarriers (Leciplex) II: improving therapeutic efficacy of quercetin on oral administration†. Mol. Pharm. 8, 716–726 (2011)PubMedCrossRef

29.

P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, M.R. Boyd, New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107–1112 (1990)PubMedCrossRef

30.

A.S. Jain, S.M. Shah, M.S. Nagarsenker, Y. Nikam, R.P. Gude, F. Steiniger, J. Thamm, A. Fahr, Lipid colloidal carriers for improvement of anticancer activity of orally delivered quercetin: formulation. Characterization and Establishing In VitroIn Vivo Advantage. J. Biomed. Nanotechnol. 9, 1230–1240 (2013)

31.

K.-I. Kusumoto, T. Ishikawa, Didodecyldimethylammonium bromide (DDAB) induces caspase-mediated apoptosis in human leukemia HL-60 cells. J. Control. Release 147, 246–252 (2010)PubMedCrossRef

32.

A.P. Nifli, P.A. Theodoropoulos, S. Munier, C. Castagnino, E. Roussakis, H.E. Katerinopoulos, J. Vercauteren, E. Castanas, Quercetin exhibits a specific fluorescence in cellular milieu: a valuable tool for the study of its intracellular distribution. J. Agric. Food Chem. 55, 2873–2878 (2007)PubMedCrossRef

33.

H.B. Liu, D. Yu, S.C. Shin, H.R. Park, J.K. Park, K.M. Bark, Spectroscopic properties of quercetin derivatives, quercetin 3 O rhamnoside and quercetin 3 O rutinoside, in hydro organic mixed solvents. Photochem. Photobiol. 85, 934–942 (2009)PubMedCrossRef

34.

P. Khumsupan, R. Ramirez, D. Khumsupan, V. Narayanaswami, Apolipoprotein E LDL receptor-binding domain-containing high-density lipoprotein: a nanovehicle to transport curcumin, an antioxidant and anti-amyloid bioflavonoid. Biochim. Biophys. Acta. 1808, 352–9 (2010)PubMedCrossRefPubMedCentral

35.

B. Senguptaand, P.K. Sengupta, Binding of quercetin with human serum albumin: a critical spectroscopic study. Biopolymers. 72, 427–434 (2003)CrossRef

36.

K. Makinoand, A. Shibata, Surface properties of liposomes depending on their composition. Adv. Planar Lipid Bilayers and Liposomes. 4, 49–77 (2006)CrossRef

37.

N. Vlachy, D. Touraud, J. Heilmann, W. Kunz, Determining the cytotoxicity of catanionic surfactant mixtures on HeLa cells. Colloid. Surf. B: Biointerfaces. 70, 278–280 (2009)PubMedCrossRef

38.

J.-H.S. Kuo, M.-S. Jan, C.-H. Chang, H.-W. Chiu, C.-T. Li, Cytotoxicity characterization of catanionic vesicles in RAW 264.7 murine macrophage-like cells. Colloid. Surf. B: Biointerfaces 41, 189–196 (2005)PubMedCrossRef

39.

S. Doktorovová, D.L. Santos, I. Costa, T. Andreani, E.B. Souto, A.M. Silva, Cationic solid lipid nanoparticles interfere with the activity of antioxidant enzymes in hepatocellular carcinoma cells. Int. J. Pharm. 471, 18–27 (2014)PubMedCrossRef

40.

C. Carbone, A. Campisi, D. Manno, A. Serra, M. Spatuzza, T. Musumeci, R. Bonfanti, G. Puglisi, The critical role of didodecyldimethylammonium bromide on physico-chemical, technological and biological properties of NLC. Colloid. Surf. B: Biointerfaces. 121, 1–10 (2014)PubMedCrossRef

41.

C.H. Liang, T.H. Chou, Effect of chain length on physicochemical properties and cytotoxicity of cationic vesicles composed of phosphatidylcholines and dialkyldimethylammonium bromides. Chem. Phys. Lipids. 158, 81–90 (2009)

42.

C. Aiello, P. Andreozzi, C. La Mesa, G. Risuleo, Biological activity of SDS-CTAB cat-anionic vesicles in cultured cells and assessment of their cytotoxicity ending in apoptosis. Colloid. Surf. B: Biointerfaces. 78, 149–154 (2010)PubMedCrossRef

43.

C. Carbone, B. Tomasello, B. Ruozi, M. Renis, G. Puglisi, Preparation and optimization of PIT solid lipid nanoparticles via statistical factorial design. Eur. J. Med. Chem. 49, 110–117 (2012)PubMedCrossRef

44.

Z. Darzynkiewiczand X. Huang. Analysis of cellular DNA content by flow cytometry. Curr. Protoc. Immunol. 5 (2004).

Titel: Apoptosis induction and anti-cancer activity of LeciPlex formulations
verfasst von: Vivek V. Dhawan
Ganesh V. Joshi
Ankitkumar S. Jain
Yuvraj P. Nikam
Rajiv P. Gude
Rita Mulherkar
Mangal S. Nagarsenker
Publikationsdatum: 01.10.2014
Verlag: Springer Netherlands
Erschienen in: Cellular Oncology / Ausgabe 5/2014
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-014-0183-7

Springer Medizin

Apoptosis induction and anti-cancer activity of LeciPlex formulations

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2014

Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells

BMP9 regulates cross-talk between breast cancer cells and bone marrow-derived mesenchymal stem cells

A novel saliva-based microRNA biomarker panel to detect head and neck cancers

Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology

Nestin involvement in tissue injury and cancer - a potential tumor marker?

Robust meta-analysis shows that glioma transcriptional subtyping complements traditional approaches

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie